AMANDA HAM: Open Payments
NPI 1912220237 · CORINTH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$36,556 in 155 payments from 9 companies in 2025. Trend: 2023 $11,143 · 2024 $5,707 · 2025 $36,556
Speaker / faculty: $28,040Consulting: $3,188Food & beverage: $2,884Travel & lodging: $2,386Education: $58
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 62 | $27,726 |
| ABBVIE INC. | 29 | $7,505 |
| E.R. Squibb & Sons, L.L.C. | 11 | $342 |
| Axsome Therapeutics, Inc. | 12 | $282 |
| Teva Pharmaceuticals USA, Inc. | 13 | $249 |
| Neurocrine BioSciences, Inc. | 14 | $229 |
| Alkermes, Inc. | 11 | $169 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
Products named: CAPLYTA, VRAYLAR, COBENFY, Auvelity, INGREZZA, AUSTEDO XR, ARISTADA, REXULTI.
Industry payments across MS — which companies pay providers there.
